Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 201 to 210 of 1090 total matches.
Ruxolitinib (Jakafi) for Myelofibrosis
The Medical Letter on Drugs and Therapeutics • Apr 02, 2012 (Issue 1387)
INTERACTIONS — In a drug interaction study,
the strong CYP3A4 inhibitor ketoconazole (Nizoral,
and others ...
The FDA has approved ruxolitinib (Jakafi – Incyte), a
janus-associated kinase (JAK) inhibitor, for treatment
of myelofibrosis. Jakafi is the first JAK inhibitor to be
approved for any indication and the only drug
approved for treatment of myelofibrosis.
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011 (Issue 1366)
out) for use during pregnancy.
DRUG INTERACTIONS — Dextromethorphan, especially
in combination ...
The FDA has approved Nuedexta (Avanir), a fixed-dose
combination of the cough suppressant dextromethorphan
hydrobromide and the antiarrhythmic
quinidine sulfate, for oral treatment of pseudobulbar
affect. The combination is the first treatment approved
by the FDA for this indication. Studies to support the
effectiveness of Nuedexta were performed in patients
with underlying amyotrophic lateral sclerosis (ALS) or
multiple sclerosis (MS); the drug has not been shown to
be safe or effective in other types of emotional lability.
In Brief: Zetia and Vytorin: The ENHANCE Study
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008 (Issue 1278)
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington
ADVISORY BOARD ...
An unpublished 2-year randomized study (ENHANCE) on the effect of adding ezetimibe 10 mg to simvastatin 80 mg in 720 patients with heterozygous familial hypercholesterolemia has been in the news recently. About 80% of these patients had previously been treated with statins. The primary endpoint was the change in the intima-media thickness (IMT) of the carotid artery (baseline 0.68 and 0.69 mm); the IMT increased by 0.0111 mm with ezetimibe plus simvastatin and 0.0058 mm with simvastatin 80 mg alone (p=0.29). The ezetimibe- simvastatin combination lowered LDL-C by 58% compared to 41% lowering...
Sitagliptin/Metformin (Janumet) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
(no adequate
studies in pregnant women) for use in pregnancy.
DRUG INTERACTIONS — Pharmacokinetic drug ...
Sitagliptin (Januvia) and metformin (Glucophage, and others) are now available in a single tablet (Janumet - Merck) for treatment of type 2 diabetes. The combination is approved by the FDA for use in patients not adequately controlled by sitagliptin or meformin alone or in those already taking both drugs. Metformin is also available in combination with the thiazolidinediones pioglitazone and rosiglitazone and with the sulfonylureas glipizide and glyburide.
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997 (Issue 1002)
in urine and partly in feces. The drug has a long half-life of
about 70 hours.
DRUG INTERACTIONS ...
Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to Alzheimer's disease. Donepezil is the second drug approved for this indication; tacrine hydrochloride (Cognex), also an acetylcholinesterase inhibitor, has been available in the USA for four years (Medical Letter, 35:87, 1993).
Comparison Table: Triptans for Migraine (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
for
Drug Interactions
With a strong CYP3A4 inhibitor6:
6.25 mg starting dose
(max 12.5 mg/day); avoid ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 doi:10.58347/tml.2023.1678b | Show Introduction Hide Introduction
Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007 (Issue 1275)
at concentrations within the therapeutic range; no
in vivo drug interaction studies have been reported.
DOSAGE ...
Levocetirizine (Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H1-antihistamine cetirizine (Zyrtec), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic idiopathic urticaria in adults and children 6 years of age and older. Cetirizine has been approved by the FDA for over-the-counter use and may also become available generically in the US. Levocetirizine has been available in Europe since 2001.
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
INTERACTIONS — Although specific drug interactions have not been studied with
trospium, it has the potential ...
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
outcomes. Colchicine is excreted in human
breast milk in low concentrations.
DRUG INTERACTIONS ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
Bexarotene (Targretin) For Cutaneous T-cell Lymphoma
The Medical Letter on Drugs and Therapeutics • Apr 03, 2000 (Issue 1075)
response occurred in 9 of 53 patients (17%) given more than 300 mg/m
2
/day.
DRUG INTERACTIONS ...
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.